ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
Phase 2
Completed
- Conditions
- Renal Anemia Associated With Chronic Renal Failure (CRF)
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 130
- Registration Number
- NCT01888445
Specified Drug Use-Results Survey of Regnite
Completed
- Conditions
- Restless Legs Syndrome
- Interventions
- Drug: Regnite
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1597
- Registration Number
- NCT01887613
Celecoxib Japan Observational Study for the Patients With Acute Pain
Completed
- Conditions
- Patients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 784
- Registration Number
- NCT01876121
Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis
Phase 1
Completed
- Conditions
- Patients on Stable Chronic Maintenance Dialysis Who Are Receiving Hemodialysis TherapyPharmacodynamics of ASP7991Pharmacokinetics of ASP7991
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 14
- Registration Number
- NCT01872026
Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder
Phase 1
Completed
- Conditions
- Major Depressive Disorder Patients
- Interventions
- Drug: FK949E
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 16
- Registration Number
- NCT01871974
Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01872013
Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers
Phase 1
Completed
- Conditions
- Plasma Concentration Change of QuetiapineHealthy
- Interventions
- Drug: FK949E
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01871987
A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)
Phase 3
Completed
- Conditions
- Diarrhea-predominant Irritable Bowel Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 577
- Registration Number
- NCT01870895
Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2015-10-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 664
- Registration Number
- NCT01870908
A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 15
- Registration Number
- NCT01754805
© Copyright 2025. All Rights Reserved by MedPath